Cargando…
Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists
Obesity is a chronic disease associated with many complications. Weight loss of 5–15% can improve many obesity-related complications. Despite the benefits of weight reduction, there are many challenges in losing weight and maintaining long-term weight loss. Pharmacotherapy can help people with obesi...
Autores principales: | Ard, Jamy, Fitch, Angela, Fruh, Sharon, Herman, Lawrence |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189979/ https://www.ncbi.nlm.nih.gov/pubmed/33977495 http://dx.doi.org/10.1007/s12325-021-01710-0 |
Ejemplares similares
-
Weight loss with glucagon‐like peptide‐1 receptor agonists in Bardet‐Biedl syndrome
por: Ganawa, Shawg, et al.
Publicado: (2022) -
Glucagon‐like peptide‐1 receptor agonists and their effects on weight reduction
por: Shin, Shyi‐Jang
Publicado: (2012) -
Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management
por: Wojtara, Magda, et al.
Publicado: (2023) -
Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity
por: Zaffina, Isabella, et al.
Publicado: (2023) -
Glucagon‐like peptide‐1 receptor agonists, weight loss, and gastric emptying: have I gut news for you
por: Jalleh, Ryan J., et al.
Publicado: (2022)